| Assay ID | Title | Year | Journal | Article |
|---|
| AID249247 | Ability to lower elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 1.4 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252277 | Myo-inositol accumulation in 3 month diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID242668 | In vitro inhibition of recombinant human aldose reductase expressed in Escherichia coli | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251202 | Improvement in motor nerve conduction velocity in 1 month diabetic rats (streptozotocin treated) at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID242605 | In vitro inhibition of recombinant human aldehyde reductase | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251594 | Motor nerve conduction velocity in 1 month diabetic rats (streptozotocin treated) measured by sciatic/tibialis-interosseous system at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236986 | Time require to reach maximum plasma concentration was determined in fasted rats after i.v. doses of 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252120 | Inhibition of sciatic nerve sorbitol accumulation in diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251403 | Percent reduction in elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 1.4 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249250 | Ability to lower elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 0.48 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249248 | Ability to lower elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 1.9 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252279 | Improvement in sorbitol accumulation in 3 month diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251595 | Motor nerve conduction velocity in 3 month diabetic rats (streptozotocin treated) measured by sciatic/tibialis-interosseous system at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249244 | Ability to lower elevated glucose levels in diabetic rats (streptozotocin treated) model at 4.8 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID598104 | Inhibition of human recombinant aldose reductase 1 after 10 mins by spectrophotometry analysis | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
| Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249249 | Ability to lower elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 4.8 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251404 | Percent reduction in elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 1.9 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236537 | Total body clearance was determined in fasted rats after i.v. doses of 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID309933 | Inhibition of aldose reductase | 2007 | Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
| Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. |
| AID251405 | Percent reduction in elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 4.8 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID598103 | Inhibition of human recombinant aldose reductase 2 expressed in Escherichia coli BL21 after 10 mins by spectrophotometry analysis | 2009 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
| Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236659 | Maximum plasma concentration was determined in fasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249245 | Ability to lower elevated glucose levels in diabetic rats (streptozotocin treated) model at 0.48 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236985 | Time require to reach maximum plasma concentration was determined in fasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236536 | Total body clearance was determined in fasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252280 | Improvement in myo-inositol accumulation in 3 month diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236433 | Area under the concentration time curve 0-24 hr was determined in fasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251596 | Motor nerve conduction velocity in 1 month diabetic rats (streptozotocin treated) measured by sciatic/tibialis-interosseous system at 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251203 | Improvement in motor nerve conduction velocity in 3 month diabetic rats (streptozotocin treated) at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251407 | Percent reduction in elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 0.48 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID1202885 | Inhibition of Wistar rat lens aldose reductase using D,L-glyceraldehyde as substrate incubated for 1 min measured for 4 mins by spectrophotometry | 2015 | Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
| Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold. |
| AID236298 | Volume of distribution was determined in fasted rats after i.v. doses of 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251204 | Improvement in motor nerve conduction velocity in 1 month diabetic rats (streptozotocin treated) at 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID237158 | Half-life was determined in fasted rats after i.v. doses of 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236538 | Total body clearance was determined in nonfasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252115 | Inhibition of sorbitol accumulation in lens of diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID237166 | Half-life was determined in nonfasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236442 | Area under the concentration time curve 0-24 h was determined in nonfasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249246 | Ability to lower elevated glucose levels in diabetic rats (streptozotocin treated) model at 0.95 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252276 | Fructose accumulation in 3 month diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID251408 | Percent reduction in elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 0.95 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252278 | Improvement in fructose accumulation in 3 month diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 5 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249251 | Ability to lower elevated plasma triglyceride levels in diabetic rats (streptozotocin treated) model at 0.95 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249243 | Ability to lower elevated glucose levels in diabetic rats (streptozotocin treated) model at 1.9 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID237157 | Half-life was determined in fasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236436 | Area under the concentration time curve 0-24 hr was determined in fasted rats after i.v. doses of 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236662 | Maximum plasma concentration was determined in fasted rats after i.v. doses of 10 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236988 | Time require to reach maximum plasma concentration was determined in nonfasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID236666 | Maximum plasma concentration was determined in nonfasted rats after p.o. doses of 6 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID252281 | Sorbitol accumulation in 3 month diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 5 mg/kg/day; BQL is Below quantifiable level | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID249242 | Ability to lower elevated glucose levels in diabetic rats (streptozotocin treated) model at 1.4 mg/kg/day | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID1797506 | Enzyme Inhibition Assay from Article 10.1021/jm0492094: \\Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabet | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| AID1346211 | Human aldo-keto reductase family 1 member B (1.-.-.- Oxidoreductases) | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |